Woodford would have paired them with Astra Zeneca. There are plenty of large pharma without much of a strong hold in the oncology space. LP’s claim of all they brought was a checkbook has turned out to be her poor analysis years back. They brought stability, experience and not so much a checkbook from the partner but willing friendly investors.
News 
Market Data 
Discover 
